Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD) – Rare Disease Research, LLC first site activated to ...

– Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event – BOULDER, Colo., June 26, 2025 /PRNewswire/ -- Edgewise Therapeutics ...

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule thera ...

Edgewise Therapeutics, Inc.,, a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced ...

BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten ...

Shares of biopharma outfit Edgewise Therapeutics (NASDAQ: EWTX) soared more than 50% today, reaching a three-year high following an update on the clinical testing of its cardiac drug EDG-7500.

BOULDER, Colo. -- (BUSINESS WIRE)-- Edgewise Therapeutics, Inc. (EWTX),, a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year ...

Over the past quarter, shares of Edgewise Therapeutics, Inc. Have risen 41.85%, and are up 211.36% in the last year. In comparison, the S&P 500 has only moved 12.57% and 27.34%, respectively.

– Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event – BOULDER, Colo., June 26, 2025 /PRNewswire/ -- Edgewise Therapeutics ...

--Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering ...